-+ 0.00%
-+ 0.00%
-+ 0.00%
BioArctic flags press release on FDA approval of Leqembi Iqlik subcutaneous starting dose
Share
Listen to the news
BioArctic flags press release on FDA approval of Leqembi Iqlik subcutaneous starting dose
  • BioArctic published an update on FDA clearance for Leqembi Iqlik subcutaneous injection as a starting dose for early Alzheimer’s disease.
  • US launch planned for late August 2026.
  • Approved initiation regimen set at 500 mg once weekly via autoinjector, delivered as two 250 mg injections.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607132237PR_NEWS_USPR_____HS03698) on July 14, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending